Cell and Gene Therapy Today—January 22, 2026
This week’s updates highlight significant advancements in gene and cell…
Rare Disease Today—January 22, 2026
This week's updates focus on significant regulatory approvals, orphan drug…
Lucid Diligence Brief: Ocugen preliminary Phase 2 data in geographic atrophy
Lucid Diligence Brief: Ocugen preliminary Phase 2 data in geographic atrophy…
Lucid Diligence Brief: Vyriad $25M Series B to take in-vivo CAR-T into clinic
Lucid Diligence Brief: Vyriad $25M Series B to take in-vivo CAR-T into clinic…
Rare Disease Video Recap—December 18, 2025
This biweekly Rare Disease Video Recap highlights the most significant…
Rare Disease Today—December 18, 2025
This week’s rare disease update spotlights key developments, regulatory…
Cell and Gene Therapy Today—December 18, 2025
This week’s Cell & Gene Therapy update highlights major developments,…
Hematology Today—December 15, 2025
This week’s hematology update spotlights key developments, regulatory…
Lucid Diligence Brief: EpilepsyGTx $33m Series A
Lucid Diligence Brief: EpilepsyGTx $33m Series A Professional audiences only.…
Immunology Today—December 10, 2025
This week’s Immunology update highlights key advances in gene therapy,…
Respiratory Today—December 5, 2025
This week’s respiratory update highlights major developments across RSV…
Rare Disease Today—December 4, 2025
This week’s rare disease update highlights key regulatory designations, early…